PSCH vs. CNCR
PSCH (Invesco S&P SmallCap Health Care ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - PSCH tracks the S&P SmallCap 600 Health Care Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. PSCH charges 0.29%/yr vs 0.79%/yr for CNCR.
Performance
PSCH vs. CNCR - Performance Comparison
Loading charts...
Returns By Period
PSCH
- 1D
- 1.28%
- 1M
- -0.71%
- YTD
- 1.80%
- 6M
- -1.68%
- 1Y
- 10.18%
- 3Y*
- 0.45%
- 5Y*
- -5.72%
- 10Y*
- 6.81%
CNCR
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
PSCH vs. CNCR - Yearly Performance Comparison
| 2026 (YTD) | |
|---|---|
PSCH Invesco S&P SmallCap Health Care ETF | 2.79% |
CNCR Loncar Cancer Immunotherapy ETF | 0.00% |
PSCH vs. CNCR - Sectors Allocation Comparison
Sectors
PSCH
CNCR
Healthcare
Technology
-
Financial Services
Industrials
-
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Real Estate
-
-
Utilities
-
-
Healthcare
PSCH
CNCR
Technology
PSCH
CNCR
-
Financial Services
PSCH
CNCR
Industrials
PSCH
CNCR
-
Basic Materials
PSCH
-
CNCR
-
Communication Services
PSCH
-
CNCR
-
Consumer Cyclical
PSCH
-
CNCR
-
Consumer Defensive
PSCH
-
CNCR
-
Energy
PSCH
-
CNCR
-
Real Estate
PSCH
-
CNCR
-
Utilities
PSCH
-
CNCR
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PSCH vs. CNCR — Risk / Return Rank
PSCH
CNCR
PSCH vs. CNCR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco S&P SmallCap Health Care ETF (PSCH) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PSCH | CNCR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 1.10 | — | — |
| Calmar ratioReturn relative to maximum drawdown | 0.67 | — | — |
| Martin ratioReturn relative to average drawdown | 1.84 | — | — |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| PSCH | CNCR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.51 | — | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.25 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.29 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.51 | — | — |
Drawdowns
PSCH vs. CNCR - Drawdown Comparison
The maximum PSCH drawdown since its inception was -46.32%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for PSCH and CNCR.
Loading charts...
Drawdown Indicators
| PSCH | CNCR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -46.32% | 0.00% | -46.32% |
Max Drawdown (1Y)Largest decline over 1 year | -15.36% | — | — |
Max Drawdown (3Y)Largest decline over 3 years | -22.98% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -46.32% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -46.32% | — | — |
Current DrawdownCurrent decline from peak | -30.59% | 0.00% | -30.59% |
Average DrawdownAverage peak-to-trough decline | -13.46% | 0.00% | -13.46% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.54% | — | — |
Volatility
PSCH vs. CNCR - Volatility Comparison
Loading charts...
Volatility by Period
| PSCH | CNCR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 4.19% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 14.06% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 20.26% | 0.00% | +20.26% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.89% | 0.00% | +22.89% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.63% | 0.00% | +23.63% |
PSCH vs. CNCR - Expense Ratio Comparison
PSCH has a 0.29% expense ratio, which is lower than CNCR's 0.79% expense ratio.
Dividends
PSCH vs. CNCR - Dividend Comparison
PSCH's dividend yield for the trailing twelve months is around 0.01%, while CNCR has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
CNCR Loncar Cancer Immunotherapy ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
PSCH Invesco S&P SmallCap Health Care ETF | 0.01% | 0.04% | 0.27% | 0.01% | 2.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% |
Frequently Asked Questions
On fees, PSCH is cheaper at 0.29% per year. The better choice depends on whether you care most about return, fees, risk, or income.
PSCH is cheaper with a 0.29% expense ratio, compared with 0.79% for CNCR.
PSCH has the higher dividend yield at 0.01%, compared with 0.00% for CNCR.
PSCH tracks S&P SmallCap 600 Health Care Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: Invesco and Exchange Traded Concepts. Their fees differ too: 0.29% for PSCH and 0.79% for CNCR.
Find the right allocation for PSCH and CNCR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer